The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
| Factor | Score | Distribution | Value | Avg | Rank |
|---|---|---|---|---|---|
Valuation | 23 | — | 20.8x | Bottom tier | |
Growth | 22 | — | 6.1% | Bottom tier | |
Quality | 1 | — | 6.6% | Bottom tier | |
Safety | 72 | 0.4x | 0.7x | Top tier | |
Capital Return | 42 | — | 2.02% | Around median | |
Momentum | 24 | -42.0% | 4.1% | Bottom tier | |
Sentiment | 82 | 9 | 3 | Top tier |
Estimates — analyst targets and a simplified DCF, not investment advice.
Summit Therapeutics Inc. (NASDAQ: SMMT) is a clinical-stage biopharmaceutical company focused on developing advanced therapies for cancer patients. The company's business model is primarily based on the development and commercialization of its promising lead compound ivonescimab, a bispecific antibody targeting both the PD-1 and VEGF pathways. The company's value is realized through strategic partnerships, particularly with its partner Akeso, which developed the drug and achieved multiple successes and approvals in China, while Summit prepares for its commercial launch in global markets upon receiving the necessary regulatory approvals.
Financially, the company does not generate operating revenues yet due to the lack of commercially approved products in its licensed territories. According to the latest financial data, the company recorded a net loss of $56.3 million in the third quarter of 2024 (loss per share of $0.08) compared to a loss of $21.3 million in the third quarter of 2023. For the full fiscal year 2024, net losses reached $221.3 million. However, the company ended 2025 with a strong financial position, holding cash and cash equivalents of approximately $713.4 million and no debt, providing it with sufficient financial flexibility to fund its intensive clinical trials and prepare for upcoming commercial launches.
Analyst consensus consensus-recommends a Buy rating for Summit Therapeutics Inc. stock, with an average price target of $19, with estimates ranging from a low of $16 to a high of $23. Based on the stock's 52-week trading range of $12.55 to $30.98 and a market capitalization of $10.9 billion, the stock trades at levels fluctuating around these targets, as the valuation reflects significant optimism regarding the upcoming approval prospects for ivonescimab in November 2026 and the ability to penetrate the massive cancer treatment market.
Figures in the text are as of 2026-06-15; the live price is shown at the top of the page.
The company's lead drug is ivonescimab (also known as ivo), a bispecific antibody that targets both PD-1 and VEGF in a single molecule. Its competitive advantage lies in its unique ability to simultaneously inhibit tumor growth and angiogenesis. It has demonstrated historic clinical superiority in Phase III trials such as HARMONi-2, which compared it directly to KEYTRUDA and showed an improvement in progression-free survival of more than 5 months on average. Furthermore, this drug represents the only bispecific platform that has recorded repeated positive readouts in this therapeutic class.
The US Food and Drug Administration (FDA) has set November 14, 2026, as the PDUFA target action date for its decision on the Biologics License Application (BLA) for ivonescimab. This application is for the treatment of patients with EGFR-mutated non-small cell lung cancer whose disease progressed after TKI therapy. The company is actively preparing by accelerating commercial readiness activities and securing supply chains and manufacturing within the United States in anticipation of a potential launch in the fourth quarter of 2026. Additionally, the company has successfully transferred and validated the drug's production process with a certified US-based manufacturer to ensure supply stability.
Automated analysis for informational purposes only — not investment advice.
The company amended the HARMONi-3 study protocol to split the analysis between the squamous and non-squamous non-small cell lung cancer cohorts, successfully completing patient screening for the squamous cohort (600 patients). The major significance for investors lies in the addition of an interim progression-free survival (PFS) analysis for this cohort in the second quarter of 2026. This analysis could open the door for early discussions with health authorities to accelerate the approval process and provide the treatment to patients faster than previous timelines. The company expects to complete patient enrollment for the non-squamous cohort in the second half of 2026, with final data expected in the first half of 2027.
The company ended 2025 in a very strong financial position, holding cash and cash equivalents of approximately $713.4 million, with its balance sheet completely free of debt. Despite recording net losses of $221.3 million in 2024, this substantial liquidity ensures the company's ability to fund its multiple ongoing clinical trials and its operating expenses, which reached $113.3 million (non-GAAP) in the final quarter of 2025. This financial solvency is further supported by the confidence of insiders and partners, as the CEO recently invested an additional $50 million in the company's stock coinciding with public offerings.
The company is leading several strategic clinical collaborations to expand the scope of ivonescimab to include innovative combination therapies. The most prominent of these collaborations include working with Revolution Medicines, where the first patient was dosed to evaluate the drug with three RAS inhibitors, and collaborating with GSK to combine the drug with its targeted B7-H3 ADC therapy, with trials planned to start in mid-2026. Additionally, the French GORTEC group is sponsoring the Phase III ILLUMINE study to evaluate the drug in the treatment of head and neck squamous cell carcinoma, involving approximately 780 patients. These multiple partnerships aim to strengthen the drug's position as a comprehensive therapeutic platform for various types of solid tumors.